Research progress of MCP-1 in the pathogenesis of Alzheimer's disease.
- Author:
Yiming XU
1
;
Qiuping LI
1
;
Siyi MAO
1
;
Kun YANG
2
;
Shuya YANG
3
,
4
Author Information
1. Regiment Four of Cadets, Basic Medical Science Academy, Air Force Medical University, Xi'an 710032, China.
2. Department of Immunology, Basic Medical Science Academy, Air Force Medical University, Xi'an 710032, China. *Corresponding authors, E-mail: yangkunkun@fmmu.edu.com.
3. Department of Immunology, Basic Medical Science Academy, Air Force Medical University, Xi'an 710032, China. *Corresponding authors, E-mail: yangshuxiaoya@
4. com.
- Publication Type:English Abstract
- MeSH:
Alzheimer Disease/metabolism*;
Humans;
Chemokine CCL2/genetics*;
Amyloid beta-Peptides/metabolism*;
Animals;
tau Proteins/metabolism*;
Biomarkers/metabolism*
- From:
Chinese Journal of Cellular and Molecular Immunology
2024;40(12):1115-1120
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer's disease (AD) is a neurodegenerative disorder with an insidious onset, primarily characterized by a progressive decline in cognitive function. MCP-1 is a cytokine with chemotactic effects on monocytes, which can regulate their migration and infiltration and participate in disease progression. Increasing evidence suggests that MCP-1 plays a key role in the progression of Alzheimer's disease and has the potential to act as an early diagnostic marker and intervention target. This paper reviews the regulatory role of MCP-1 in neuroinflammation, beta-amyloid (Aβ) deposition and Tau pathology, and explores the potential of MCP-1 as a biomarker and intervention target for the early diagnosis of Alzheimer's disease.
